FOLH1 and neoplasm: Compared with reported data for the tumour effective half-life of 177Lu-PSMA-617 (61 h) and 177Lu-PSMA-I&T (43 h), our estimate for 177Lu-rhPSMA-10.1 (91 h) suggests 177Lu-rhPSMA-10.1 offers notably longer retention in tumours than achieved with other 177Lu-labelled PSMA RLT agents [34].